Stay updated on Pembrolizumab in HER2+ Gastric Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.

Latest updates to the Pembrolizumab in HER2+ Gastric Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedLocation entry updated from Padua, Italy, 35128 to Padova, Italy, 35128 in the study's locations list.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedNapoli, Italy, 80131 was renamed to Naples, Italy, 80131, and the page revision updated to v3.5.0.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check60 days agoChange DetectedAdded a 'Gastric cancer' tag and a link to the Genetic and Rare Diseases Information Center; page revision updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check68 days agoChange DetectedA new revision label 'Revision: v3.4.1' appears and the previous 'Revision: v3.4.0' label is removed; this is a minor version update not affecting trial details.SummaryDifference0.0%

- Check82 days agoChange DetectedThe page adds a glossary toggle and new metadata fields (Last Update Submitted that Met QC Criteria, Last Update Posted) plus an updated revision label (v3.4.0). It removes older items (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in HER2+ Gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.